Clinical characteristics of childhood cancer survivors treated with potentially pulmotoxic therapy
| Characteristic | Original cohort n (%) | Study group n (%) | Follow-up group* n (%) |
| No. of childhood cancer survivors | 248 | 220 | 193 |
| Sex | |||
| Male | 136 (54.8) | 117 (53.2) | 103 (53.4) |
| Female | 112 (45.2) | 103 (46.8) | 90 (46.6) |
| Primary childhood cancer diagnosis | |||
| Leukaemia | 34 (13.7) | 28 (12.7) | 23 (11.9) |
| Lymphoma | 131 (52.8) | 121 (55.0) | 110 (57.0) |
| Hodgkin | 62 (25.0) | 57 (25.9) | 52 (26.9) |
| Non-Hodgkin | 69 (27.8) | 64 (29.1) | 58 (30.1) |
| Renal tumour | 19 (7.7) | 16 (7.3) | 13 (6.7) |
| Brain/CNS tumour | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Bone tumour | 30 (12.1) | 23 (10.4) | 20 (10.4) |
| Soft tissue sarcoma | 6 (2.4) | 5 (2.3) | 4 (2.1) |
| Neuroblastoma | 9 (3.6) | 9 (4.1) | 7 (3.6) |
| Other | 19 (7.7) | 18 (8.2) | 16 (8.3) |
| Age at diagnosis, median (range) years | 10.0 (0.0–17.1) | 9.9 (0.0–17.1) | 10.3 (0.0–16.8) |
| 0–4 years | 51 (20.6) | 47 (21.4) | 34 (17.6) |
| 5–9 years | 71 (28.6) | 65 (29.5) | 59 (30.6) |
| 10–14 years | 100 (40.3) | 84 (38.2) | 78 (40.4) |
| 15–18 years | 26 (10.5) | 24 (10.9) | 22 (11.4) |
| Follow-up duration after diagnosis, median (range) years† | NA | NA | 17.9 (5.6–36.8) |
| 5–9 years | 20 (10.4) | ||
| 10–14 years | 45 (23.3) | ||
| 15–19 years | 50 (25.9) | ||
| 20–24 years | 40 (20.7) | ||
| ≥25 years | 38 (19.7) | ||
| Age at follow-up, median (range) years† | NA | NA | 27.3 (18.2–47.0) |
| 18–19 years | 22 (11.4) | ||
| 20–24 years | 47 (24.4) | ||
| 25–29 years | 49 (25.4) | ||
| 30–34 years | 40 (20.7) | ||
| ≥35 years | 35 (18.1) | ||
| Bleomycin, median cumulative dose (range) mg/m2 | 60.0 (6.0–594.0) | 60.0 (10.0–594.0) | 60.0 (10.0–594.0) |
| Yes | 134 (54.0) | 124 (56.4) | 110 (57.0) |
| No | 114 (46.0) | 96 (43.6) | 83 (43.0) |
| Radiotherapy, median cumulative dose (range) Gy | 21.0 (3.0–60.0) | 24.3 (3.0–60.0) | 23.0 (3.0–60.0) |
| Yes | 103 (41.5) | 86 (39.1) | 79 (40.9) |
| Complete thorax | 20 (8.1) | 15 (6.8) | 13 (6.7) |
| Part of thorax | 30 (12.1) | 27 (12.3) | 26 (13.5) |
| Mediastinum | 33 (13.3) | 29 (13.2) | 26 (13.5) |
| TBI | 20 (8.1) | 15 (6.8) | 14 (7.3) |
| No | 145 (58.5) | 134 (60.9) | 114 (59.1) |
| Surgery | |||
| Yes | 47 (19.0) | 40 (18.2) | 32 (16.6) |
| Metastasectomy unilateral | 14 (5.6) | 13 (5.9) | 9 (4.7) |
| Metastasectomy bilateral | 15 (6.0) | 12 (5.4) | 11 (5.7) |
| Lobectomy | 4 (1.6) | 1 (0.5) | 0 (0.0) |
| Pneumonectomy | 1 (0.4) | 1 (0.5) | 1 (0.0) |
| Thoracic wall resection | 5 (2.0) | 5 (2.3) | 5 (2.6) |
| Other | 8 (3.2) | 8 (3.6) | 6 (3.1) |
| No | 201 (81.0) | 180 (81.8) | 161 (83.4) |
| Overall treatment | |||
| Bleomycin only | 120 (48.4) | 111 (50.5) | 98 (50.8) |
| Radiotherapy only | 70 (28.2) | 59 (26.8) | 54 (28.0) |
| Surgery only | 22 (8.9) | 20 (9.1) | 13 (6.7) |
| Bleomycin with radiotherapy | 11 (4.4) | 10 (4.5) | 9 (4.7) |
| Bleomycin with surgery | 3 (1.2) | 3 (1.4) | 3 (1.6) |
| Radiotherapy with surgery | 22 (8.9) | 17 (7.7) | 16 (8.3) |
| Bleomycin with radiotherapy and surgery | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Other chemotherapy | |||
| HD cyclophosphamide | 52 (21.0) | 47 (21.4) | 43 (22.3) |
| Melphalan | 6 (2.4) | 3 (1.4) | 3 (1.6) |
| Busulphan | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Lomustine | 1 (0.4) | 0 (0.0) | 0 (0.0) |
| Carmustine | 3 (1.2) | 3 (1.4) | 3 (1.6) |
| Other | 231 (93.1) | 204 (92.7) | 180 (93.3) |
| Recurrence of primary tumour | |||
| Yes | 81 (32.7) | 64 (29.1) | 54 (28.0) |
| No | 167 (67.3) | 156 (70.9) | 139 (72.0) |
| Vital status | |||
| Living | 229 (92.3) | 216 (98.2) | 191 (99.0) |
| Died | 19 (7.7) | 4 (1.8) | 2 (1.0) |